Titre du document / Document title

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma : Results in twenty-nine patients

Auteur(s) / Author(s)

ZACKHEIM H. S. ⁽¹⁾ ; MOHAMMED KASHANI-SABET ⁽¹⁾ ; HWANG S. T. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Dermatology, University of California, San Francisco, California, ETATS-UNIS

Résumé / Abstract

Background : Most patients with erythrodermic cutaneous T-cell lymphoma (CTCL) have intense, generalized, refractory pruritus. In some large series the median survival was approximately 3 years. Objective : Our purpose was to review our experience with methotrexate in the treatment of 29 patients with erythrodermic CTCL observed for up to 129 months. Methods : This is a retrospective study. Data are presented in terms of response rates, freedom from treatment failure, and overall survival. Results : Twelve patients (41%) achieved complete remission, and five (17%) achieved partial remission for a total response rate of 58%. The median freedom from treatment failure was 31 months, and the median survival was 8.4 years. Side effects caused treatment failure in only two patients. Conclusion : Low-dose methotrexate is a valuable first-line treatment for the majority of patients with early to intermediate-stage erythrodermic CTCL.

Revue / Journal Title

Journal of the American Academy of Dermatology   ISSN 0190-9622   CODEN JAADDB 

Source / Source

1996, vol. 34, n^o4, pp. 626-631 (16 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, New York, NY, ETATS-UNIS  (1979) (Revue)

Mots-clés anglais / English Keywords

Lymphoma ; T-Lymphocyte ; Skin ; Low dose ; Treatment ; Chemotherapy ; Antineoplastic agent ; Antimetabolic ; Antifolate ; Human ; Malignant hemopathy ; Lymphoproliferative syndrome ; Cutaneous hematologic disease ;

Mots-clés français / French Keywords

Lymphome ; Lymphocyte T ; Peau ; Méthotrexate ; Dose faible ; Traitement ; Chimiothérapie ; Anticancéreux ; Antimétabolite ; Antifolate ; Homme ; Hémopathie maligne ; Lymphoprolifératif syndrome ; Hématodermie ;

Mots-clés espagnols / Spanish Keywords

Linfoma ; Linfocito T ; Piel ; Dosis débil ; Tratamiento ; Quimioterapia ; Anticanceroso ; Antimetabólito ; Antifolato ; Hombre ; Hemopatía maligna ; Linfoproliferativo síndrome ; Hematodermia ;

Localisation / Location

INIST-CNRS, Cote INIST : 18387, 35400004467347.0070